Disclaimer
The alfapump® system is currently not approved in the United States or Canada. In the United States and Canada, the alfapump® system is currently under clinical investigation (POSEIDON Study) and is being studied in adult patients with refractory or recurrent ascites due to cirrhosis. DSR® therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. There is no link between the DSR® therapy and ongoing investigations with the alfapump® system in Europe, the United States or Canada.
6 questions to CEO Ian Crosbie, May 2023
alfapump DSR® – combines Sequana Medical’s breakthrough DSR therapy with its alfapump®
DSR® – potential new treatment for diuretic-resistant fluid overload due to heart failure
Heart failure and diuretic-resistant fluid overload
alfapump® – new ascites treatment for more quality of life
Recovered quality of life with the alfapump® system
Ascites and NASH related Cirrhosis
The alfapump® for the management of fluid overload
POSEIDON study interim results – November 2020
RED DESERT study interim results – October 2020
alfapump DSR® therapy in heart failure